125 related articles for article (PubMed ID: 38215351)
1. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
Stinchcombe TE; Wang X; Damman B; Mentlick J; Landreneau R; Wigle D; Jones DR; Conti M; Ashrafi AS; Liberman M; de Perrot M; Mitchell JD; Keenan R; Bauer T; Miller D; Altorki N
J Clin Oncol; 2024 Apr; 42(10):1110-1113. PubMed ID: 38215351
[No Abstract] [Full Text] [Related]
2. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.
Altorki N; Wang X; Kozono D; Watt C; Landrenau R; Wigle D; Port J; Jones DR; Conti M; Ashrafi AS; Liberman M; Yasufuku K; Yang S; Mitchell JD; Pass H; Keenan R; Bauer T; Miller D; Kohman LJ; Stinchcombe TE; Vokes E
N Engl J Med; 2023 Feb; 388(6):489-498. PubMed ID: 36780674
[TBL] [Abstract][Full Text] [Related]
3. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance).
Altorki N; Wang X; Damman B; Mentlick J; Landreneau R; Wigle D; Jones DR; Conti M; Ashrafi AS; Liberman M; de Perrot M; Mitchell JD; Keenan R; Bauer T; Miller D; Stinchcombe TE
J Thorac Cardiovasc Surg; 2024 Jan; 167(1):338-347.e1. PubMed ID: 37473998
[TBL] [Abstract][Full Text] [Related]
4. Lobar or sublobar resection for early-stage second primary lung cancer ≤ 3 cm in size: a SEER population-based study.
Zhao K; Xia C; Qiu M; Yang Z; Cui T; Song T; Li S; Mei H; Zheng Y; Wang H
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16679-16690. PubMed ID: 37725243
[TBL] [Abstract][Full Text] [Related]
5. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
Altorki NK; Wang X; Wigle D; Gu L; Darling G; Ashrafi AS; Landrenau R; Miller D; Liberman M; Jones DR; Keenan R; Conti M; Wright G; Veit LJ; Ramalingam SS; Kamel M; Pass HI; Mitchell JD; Stinchcombe T; Vokes E; Kohman LJ
Lancet Respir Med; 2018 Dec; 6(12):915-924. PubMed ID: 30442588
[TBL] [Abstract][Full Text] [Related]
6. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.
Rice D; Kim HW; Sabichi A; Lippman S; Lee JJ; Williams B; Vaporciyan A; Smythe WR; Swisher S; Walsh G; Putnam JB; Hong WK; Roth J
Ann Thorac Surg; 2003 Oct; 76(4):1001-7; discussion 1007-8. PubMed ID: 14529975
[TBL] [Abstract][Full Text] [Related]
7. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules.
Altorki NK; Yip R; Hanaoka T; Bauer T; Aye R; Kohman L; Sheppard B; Thurer R; Andaz S; Smith M; Mayfield W; Grannis F; Korst R; Pass H; Straznicka M; Flores R; Henschke CI;
J Thorac Cardiovasc Surg; 2014 Feb; 147(2):754-62; Discussion 762-4. PubMed ID: 24280722
[TBL] [Abstract][Full Text] [Related]
8. Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.
Leroy T; Monnet E; Guerzider S; Jacoulet P; De Bari B; Falcoz PE; Gainet-Brun M; Lahourcade J; Alfreijat F; Almotlak H; Adotevi O; Pernet D; Polio JC; Desmarets M; Woronoff AS; Westeel V
Lung Cancer; 2019 Nov; 137():23-30. PubMed ID: 31521979
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Resection for Second Lung Cancer After Pneumonectomy: A Population-Based Study.
Ayub A; Rehmani SS; Al-Ayoubi AM; Raad W; Flores RM; Bhora FY
Ann Thorac Surg; 2017 Oct; 104(4):1131-1137. PubMed ID: 28709663
[TBL] [Abstract][Full Text] [Related]
10. Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Zhang Z; Zhang B; Wang C
J Clin Oncol; 2022 Dec; 40(34):3912-3917. PubMed ID: 36027483
[No Abstract] [Full Text] [Related]
11. Prognostic Significance of Lymph Node Count Removed at Sublobar Resection in Pathologic Stage IA Non-Small-cell Lung Cancer: A Population-Based Analysis.
He Z; Li Z; Xu S; Wu W; Zhu Q; Wang J; Wen W; Chen L
Clin Lung Cancer; 2021 Jul; 22(4):e563-e573. PubMed ID: 33214078
[TBL] [Abstract][Full Text] [Related]
12. Sublobar resection versus lobectomy in Surgical Treatment of Elderly Patients with early-stage non-small cell lung cancer (STEPS): study protocol for a randomized controlled trial.
Yang F; Sui X; Chen X; Zhang L; Wang X; Wang S; Wang J
Trials; 2016 Apr; 17():191. PubMed ID: 27053091
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy.
Verstegen NE; Lagerwaard FJ; Hashemi SM; Dahele M; Slotman BJ; Senan S
J Thorac Oncol; 2015 Aug; 10(8):1195-200. PubMed ID: 26200274
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of sublobar resection vs lobectomy for invasive clinical stage T1N0 non-small-cell lung cancer: A propensity-match analysis.
Wald O; Sadeh BM; Bdolah-Abram T; Erez E; Shapira OM; Izhar U
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1339. PubMed ID: 33570255
[TBL] [Abstract][Full Text] [Related]
15. Prognostic study for survival outcome following the treatment of second primary lung cancer in patients with previously resected non-small cell lung cancer.
Wu Y; Han C; Chong Y; Liu J; Gong L; Wang Z; Liang N
Thorac Cancer; 2020 Oct; 11(10):2840-2851. PubMed ID: 32851789
[TBL] [Abstract][Full Text] [Related]
16. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
Mahmood S; Bilal H; Faivre-Finn C; Shah R
Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
[TBL] [Abstract][Full Text] [Related]
17. Sublobar resection with intraoperative brachytherapy versus sublobar resection alone for early-stage non-small-cell lung cancer: a meta-analysis.
Chen E; Wang J; Jia C; Min X; Zhang H
Interact Cardiovasc Thorac Surg; 2021 Aug; 33(3):377-384. PubMed ID: 34037754
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of surgical outcomes and prognostic factors of second primary lung cancer based on a systematic review and meta-analysis.
Zhao J; Shen Z; Huang Y; Zhao G; Wang W; Yang Y; Zhou C; Ye L
BMC Surg; 2023 Apr; 23(1):95. PubMed ID: 37085804
[TBL] [Abstract][Full Text] [Related]
19. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
20. Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H; Yamamoto N; Misumi T; Yoh K; Saito H; Sugawara S; Yamazaki K; Nakagawa K; Sugio K; Seto T; Toyooka S; Date H; Mitsudomi T; Okamoto I; Yokoi K; Saka H; Okamoto H; Takiguchi Y; Takahashi T; Tsuboi M
J Clin Oncol; 2023 Dec; 41(34):5242-5246. PubMed ID: 37656928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
